Filana Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Filana Therapeutics, Inc. (FLNA) had Available-for-sale Securities, Amortized Cost Basis of $2.10 million as of 2016-12-31, per its 10-K filed 2018-02-06.
Discontinued › Notes
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-02-06
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $2.10M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2016-12-31 | $2.10M 10-K · filed 2018-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |